Detalles de la búsqueda
1.
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Oncologist
; 28(6): 551-e454, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37053467
2.
Staphylococcus haemolyticus attenuates the antibacterial effect of teicoplanin via aggregates and biofilms.
Microb Pathog
; 180: 106152, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37178725
3.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist
; 27(11): 903-e834, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181763
4.
[Strategy with Immune Checkpoint Inhibitors for ESâSCLC].
Gan To Kagaku Ryoho
; 48(4): 493-498, 2021 Apr.
Artículo
en Japonés
| MEDLINE | ID: mdl-33976031
5.
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
Ann Am Thorac Soc
; 21(4): 635-643, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38364204
6.
Predictors of central line-associated bloodstream infections in cancer patients undergoing chemotherapy through implanted venous access ports: a retrospective, observational study.
Transl Cancer Res
; 12(12): 3538-3546, 2023 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38192991
7.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Cancer Med
; 12(14): 15117-15127, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269194
8.
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.
JTO Clin Res Rep
; 4(12): 100593, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38046378
9.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.
Ther Adv Med Oncol
; 14: 17588359221142786, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36570411
10.
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).
Ther Adv Med Oncol
; 14: 17588359221116603, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35923924
11.
[CPT-11 chemotherapy for a hemodialysis patient with small-cell lung cancer].
Gan To Kagaku Ryoho
; 38(9): 1499-502, 2011 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-21918349
12.
Effect of Adjuvant and Palliative Chemotherapy in Large Cell Neuroendocrine Carcinoma of the Lung: A Systematic Review and Meta-Analysis.
Cancers (Basel)
; 13(23)2021 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34885057
13.
Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638357
14.
Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Thorac Cancer
; 12(5): 613-618, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33448648
15.
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Transl Lung Cancer Res
; 10(1): 221-232, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569306
16.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Ther Adv Med Oncol
; 13: 1758835921998588, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33717228
17.
Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from Hormonal Therapy-related Femoral Pain.
Intern Med
; 59(6): 855-857, 2020 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31761883
18.
Successful Treatment with Taxane-Based Chemotherapy in Advanced Sebaceous Carcinoma: A Case Report and Literature Review.
Case Rep Oncol
; 12(1): 47-52, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792644
19.
Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.
Case Rep Oncol
; 12(1): 84-90, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792647
20.
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.
Case Rep Oncol
; 12(1): 91-97, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30792648